A carregar...
Publicação
Dinamização do banco de tumores do IPO Lisboa: a caminho da referência nacional
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 19.87 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
RESUMO: A investigação translacional requer grandes séries de casos. O cancro é uma
doença multifatorial complexa sendo o acesso a amostras biológicas frescas
crucial para o seu estudo. Os biobancos e, particularmente as redes
internacionais, assumem assim uma posição estratégica no avanço da
investigação biomédica, contexto em que a partilha de amostras e dados
associados se revela tão importante quanto desafiante. Para além das inúmeras
responsabilidades éticas e legais, o maior desafio de um biobanco está na sua
sustentabilidade. Diretamente relacionada com a sustentabilidade está a
qualidade das amostras e dados armazenados, pelo que a padronização de
políticas, procedimentos e processos com reconhecimento internacional é
fundamental. O IPO de Lisboa, fundado em 1923, é o hospital oncológico com
maior cobertura geográfica do país e dispõe de um Banco de Tumores (BT)
desde 2009 necessitando de uma reavaliação para estabelecer o seu
crescimento sustentável em cumprimento da sua função de suporte à
investigação em oncologia. Com base na análise da opinião dos seus
colaboradores (inquérito), análise de competitividade de mercado e análise
SWOT, este trabalho apresenta: i) uma proposta de posicionamento estratégico
com a (re)definição da visão, missão e valores do BT; ii) um modelo de negócio
sem fins lucrativos com definição clara da sua proposta de valor; iii) um modelo
de governança com alargamento substancial da rede de consultores envolvendo
toda a cadeia de fornecimento; e iv) uma proposta de sustentabilidade assente
em três pilares ao nível operacional, financiero e social. Com a vantagem do
suporte institucional, o primeiro passo passará pela otimização ao nível da
estrutura, organização e funcionamento com pouco investimento de capital. É
essencial aumentar o acesso efetivo às coleções armazenadas, com base em
políticas de justiça, responsabilização, transparência e monitorização adequada
para garantir a confiança e o envolvimento de todos os seus atores-chave.
Assumindo uma posição de liderança na área, os elementos do BT do IPO de
Lisboa poderão ainda potenciar a dicussão pública, assim como a revisão da
legislação nacional em matéria de investigação biomédica
ABSTRACT: Translational research requires large series of cases whilst cancer, being a complex multifactor disease, demands for access to fresh biological material for its investigation. Thus, biobanks and international networks play a strategic role in the development of biomedical research. In this context, sample and data sharing is as important as challenging. Besides many ethical and legal responsibilities, the major challenge of a biobank is its sustainability. Sample and data quality are directly related to a biobank’s sustainability for which the development and implementation of internationally recognized standards (policies, procedures and processes) are crucial. IPO Lisboa, established in 1923, is the largest cancer hospital in Portugal and has a Tumour Biobank since 2009, requiring a general reassessment to determine its long-term sustainability and growth towards its mission: supporting oncology research. Based on the opinion of its collaborators (questionnaire), market competitive analysis and SWOT analysis, this work hereby presents: i) a proposal of strategic positioning (re)defining the vision, mission and values of the Tumour Biobank; ii) a (not for profit) business model clearly defining its value proposition; iii) a governance model with a substantial extension of its network of consultants along the whole chain of provision; and iv) a proposal of sustainability built on three pillars: organizational, financial and social levels. Taking advantage of the full institutional support, the first step will be the optimization of its current structure, organization and functioning with little capital investment. It is paramount to increase the effective access to the stored collections based on policies of justice, accountability, transparency, and proper monitoring to ensure trust and involvement of all stakeholders. By assuming a leadership position in the area, the elements of the Tumour Biobank of IPO Lisboa may promote public discussion as well as shape national law revision on biomedical research.
ABSTRACT: Translational research requires large series of cases whilst cancer, being a complex multifactor disease, demands for access to fresh biological material for its investigation. Thus, biobanks and international networks play a strategic role in the development of biomedical research. In this context, sample and data sharing is as important as challenging. Besides many ethical and legal responsibilities, the major challenge of a biobank is its sustainability. Sample and data quality are directly related to a biobank’s sustainability for which the development and implementation of internationally recognized standards (policies, procedures and processes) are crucial. IPO Lisboa, established in 1923, is the largest cancer hospital in Portugal and has a Tumour Biobank since 2009, requiring a general reassessment to determine its long-term sustainability and growth towards its mission: supporting oncology research. Based on the opinion of its collaborators (questionnaire), market competitive analysis and SWOT analysis, this work hereby presents: i) a proposal of strategic positioning (re)defining the vision, mission and values of the Tumour Biobank; ii) a (not for profit) business model clearly defining its value proposition; iii) a governance model with a substantial extension of its network of consultants along the whole chain of provision; and iv) a proposal of sustainability built on three pillars: organizational, financial and social levels. Taking advantage of the full institutional support, the first step will be the optimization of its current structure, organization and functioning with little capital investment. It is paramount to increase the effective access to the stored collections based on policies of justice, accountability, transparency, and proper monitoring to ensure trust and involvement of all stakeholders. By assuming a leadership position in the area, the elements of the Tumour Biobank of IPO Lisboa may promote public discussion as well as shape national law revision on biomedical research.
Descrição
Palavras-chave
Biobanco Banco de tumores IPOLFG Governança Sustentabilidade Biobanking Tumour bank IPOLFG Governance Sustainability